Drug intelligence / Profile preview

guttiferone J

Development stage: Preclinical
Modality: Small Molecules
Administration: Oral

Overview

Guttiferone J is a polyisoprenylated benzophenone isolated from the fruits of *Garcinia cambogia*. It is currently being researched as a potential anti-obesity agent due to its ability to induce the browning of white adipose tissue (WAT). The mechanism of action involves the activation of Sirtuin 3 (SIRT3), a mitochondrial protein that plays a key role in metabolic regulation and thermogenesis. By converting energy-storing white fat into energy-burning beige fat, guttiferone J may offer a novel pharmacological approach to managing body weight and metabolic health.

Targets

SIRT3 (NAD-dependent protein deacetylase sirtuin-3)

Beyond the preview

Go deeper on guttiferone J.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on guttiferone J.

Explore the full profile